Artivion
AORT

$27.48

0.07%

Market Cap: 1.15B

About: Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others.

Employees: 1,500

Healthcare Surgical & Medical Instruments & Apparatus

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 6 analysts

0

News positive %

of 3 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

1,988% more call options, than puts

Call options by funds: $668K | Put options by funds: $32K

60% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 15

22% more capital invested

Capital invested by funds: $610M [Q4 2023] → $742M (+$132M) [Q1 2024]

6% more funds holding

Funds holding: 140 [Q4 2023] → 149 (+9) [Q1 2024]

1.98% more ownership

Funds ownership: 83.08% [Q4 2023] → 85.06% (+1.98%) [Q1 2024]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 1 (+0) [Q1 2024]

26% less repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 53

See Fund Rankings

Research analyst outlook

6 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$22

20%

downside

Avg. target

$26

5%

downside

High target

$30

9%

upside

6 analyst ratings

6 positive

100%

0 neutral

0%

0 negative

0%

Lake Street Frank Takkinen	9%upside $30	Buy Maintained	2 Jul 2024
Stifel Rick Wise	9%downside $25	Buy Maintained	7 May 2024
Needham Mike Matson	9%upside $30	Buy Maintained	7 May 2024
Needham Mike Matson	9%downside $25	Buy Maintained	8 Apr 2024
Stifel Rick Wise	20%downside $22	Buy Maintained	16 Feb 2024

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about AORT published over the past 30 days

Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2024 Financial Results

ATLANTA , July 25, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2024 financial results will be released on Thursday, August 8, 2024 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m.

Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2024 Financial Results

3 Earnings All-Stars With More Room to Run

Earnings are essential to determining which stocks will outperform. Unsurprisingly, earnings outperformers also see strong price appreciation.

3 Earnings All-Stars With More Room to Run

Artivion Amends Agreements with Endospan

Provides Endospan with $25 million of Additional Debt Funding to Obtain FDA Approval for NEXUS Upfront Payment Associated with Purchase Option Reduced to $135 million, inclusive of loan off-set, and $100 million earnout minimum eliminated ATLANTA , July 1, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced it has amended its credit facility and option purchase agreements with Endospan Ltd. ("Endospan"), an Israeli-based, privately-held developer of the NEXUS® Stent Graft System ("NEXUS").

Artivion Amends Agreements with Endospan

Data-Driven Growth Fuels More Upside For Overlooked Artivion

Artivion, Inc. has continued to log double-digit revenue growth with contributions from diverse assets including its stent grafts, heart valves, and cryopreserved tissue grafts. Positive post-approval trial data for the On-X aortic valve and a successful PERSEVERE IDE study for AMDS hybrid prosthesis can drive additional revenue growth. A strong pipeline, including NEXUS and ARCEVO stent graft systems, can support a longer runway of continued revenue growth.

Data-Driven Growth Fuels More Upside For Overlooked Artivion

Zacks Investment Research

Artivion, Inc. (AORT) Hit a 52 Week High, Can the Run Continue?

Artivion (AORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Artivion, Inc. (AORT) Hit a 52 Week High, Can the Run Continue?

Artivion, Inc. (AORT) Q1 2024 Earnings Call Transcript

Artivion, Inc. (NYSE:AORT ) Q1 2024 Earnings Conference Call May 6, 2024 4:30 PM ET Company Participants Eileen Martin - Investor Relations Pat Mackin - Chief Executive Officer Lance Berry - Chief Financial Officer Conference Call Participants Mike Matson - Needham & Company Suraj Kalia - Oppenheimer & Company Frank Takkinen - Lake Street Capital Markets Jeffrey Cohen - Ladenburg Thalmann Operator Greetings. Welcome to Artivion First Quarter 2024 Financial Conference Call.

Artivion, Inc. (AORT) Q1 2024 Earnings Call Transcript

Zacks Investment Research

Artivion (AORT) Tops Q1 Earnings and Revenue Estimates

Artivion (AORT) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.02 per share a year ago.

Artivion (AORT) Tops Q1 Earnings and Revenue Estimates

Artivion Reports First Quarter 2024 Financial Results

First Quarter Highlights: Achieved revenue of $97.4 million in the first quarter of 2024 versus $83.2 million in the first quarter of 2023, an increase of 17% on a GAAP basis and 16% on a non-GAAP constant currency basis Net income was $7.5 million or $0.18 per fully diluted share and non-GAAP net income was $2.6 million or $0.06 per fully diluted share in the first quarter of 2024 Non-GAAP adjusted EBITDA increased 60% to $17.3 million in the first quarter of 2024 compared to $10.8 million in the first quarter of 2023 Revised FY24 revenue guidance to 9% to 12% year-over-year growth on a constant currency basis, an increase of 0.5% at the midpoint ATLANTA , May 6, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the first quarter ended March 31, 2024. "We are very pleased with our first quarter results as we maintained growth momentum and executed on key operational priorities.

Artivion Reports First Quarter 2024 Financial Results

Artivion Announces Presentation of New Clinical Data for On-X Aortic Heart Valve and AMDS at the 104th American Association for Thoracic Surgery (AATS) Annual Meeting

5-Year Real-World Safety and Efficacy Data from On-X Aortic Heart Valve Low INR Post-Market Study Demonstrate Even Better Patient Outcomes Than Predicted by the PROACT IDE Study Late-Breaking 30-Day Data from AMDS PERSEVERE Trial Demonstrate Positive Aortic Remodeling Outcomes and Zero DANE Tears ATLANTA , April 29, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of new clinical data from the On-X Low INR post-market study and AMDS PERSEVERE Trial at the 104th American Association for Thoracic Surgery (AATS) Annual Meeting in Toronto, Canada. Presentations highlighted 5-year real-world safety and efficacy data from the On-X Aortic Heart Valve Low INR post-market study that demonstrate even better patient outcomes than predicted by the On-X Aortic Heart Valve PROACT IDE Study, as well as Late-Breaking data from the AMDS PERSEVERE Trial demonstrating, at 30-days post-AMDS implantation, positive aortic remodeling outcomes and zero distal anastomotic new entry (DANE) tears.

Artivion Announces Presentation of New Clinical Data for On-X Aortic Heart Valve and AMDS at the 104th American Association for Thoracic Surgery (AATS) Annual Meeting

Artivion Announces Release Date and Teleconference Call Details for First Quarter 2024 Financial Results

ATLANTA , April 22, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2024 financial results will be released on Monday, May 6, 2024 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m.

Artivion Announces Release Date and Teleconference Call Details for First Quarter 2024 Financial Results

See News Rankings